Explore more publications!
STEM Review Turks & Caicos
Got News to Share?

STEM Review Turks & Caicos: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on STEM Review Turks & Caicos.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on October 9, 2025

New Crypto Mutuum Finance (MUTM) Raises Over $17 Million Ahead of V1 Lending Protocol Launch in Q4 2025
October 9, 2025

New Crypto Mutuum Finance (MUTM) Raises Over $17 Million Ahead of V1 Lending Protocol Launch in Q4 2025

Indeterminate GlobeNewswire
XION Integrates with Fireblocks Infrastructure to Reach 2,400+ Institutions and a Network with $10T in Digital Asset Transactions Secured
October 9, 2025

XION Integrates with Fireblocks Infrastructure to Reach 2,400+ Institutions and a Network with $10T in Digital Asset Transactions Secured

Indeterminate GlobeNewswire
Clyx Partners with Selena Gomez and Mandy Teefey’s Wondermind to Launch Series of Wellness Events in NYC
October 9, 2025

Clyx Partners with Selena Gomez and Mandy Teefey’s Wondermind to Launch Series of Wellness Events in NYC

Indeterminate GlobeNewswire
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
October 9, 2025

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

Indeterminate GlobeNewswire
Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment
October 9, 2025

Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment

Indeterminate GlobeNewswire
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
October 9, 2025

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Indeterminate GlobeNewswire
Lantronix to Showcase Edge AI Drone Platform at AUSA 2025, Highlighting Strategic Partnerships and UAV Innovations
October 9, 2025

Lantronix to Showcase Edge AI Drone Platform at AUSA 2025, Highlighting Strategic Partnerships and UAV Innovations

Indeterminate GlobeNewswire
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
October 9, 2025

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

Indeterminate GlobeNewswire
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
October 9, 2025

Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients

Indeterminate GlobeNewswire
Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025
October 9, 2025

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

Indeterminate GlobeNewswire
Aduro Clean Technologies Advances Demonstration Plant Program; Begins Global Site Selection Project
October 9, 2025

Aduro Clean Technologies Advances Demonstration Plant Program; Begins Global Site Selection Project

Indeterminate GlobeNewswire
Tilray Brands Reports Strong First Quarter Fiscal 2026 Results, Highlighting Continued Growth with Record Q1 Net Revenue of $210 Million and Net Income
October 9, 2025

Tilray Brands Reports Strong First Quarter Fiscal 2026 Results, Highlighting Continued Growth with Record Q1 Net Revenue of $210 Million and Net Income

Indeterminate GlobeNewswire
Rail Vision Signs Term Sheet to Boost Growth with Advanced AI Acquisition of 51% Stake in Quantum Transportation
October 9, 2025

Rail Vision Signs Term Sheet to Boost Growth with Advanced AI Acquisition of 51% Stake in Quantum Transportation

Indeterminate GlobeNewswire
U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade
October 9, 2025

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Indeterminate GlobeNewswire
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
October 9, 2025

Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion

Indeterminate GlobeNewswire
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial
October 9, 2025

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Indeterminate GlobeNewswire
CTi Welcomes Dr. Luis F. Quintero to Advisory Board, Strengthening Focus on Oil & Gas and Frack & Produced Water
October 9, 2025

CTi Welcomes Dr. Luis F. Quintero to Advisory Board, Strengthening Focus on Oil & Gas and Frack & Produced Water

Indeterminate GlobeNewswire
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
October 9, 2025

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Indeterminate GlobeNewswire
Rackspace Technology Receives Silver Award from UK Armed Forces Covenant
October 9, 2025

Rackspace Technology Receives Silver Award from UK Armed Forces Covenant

Indeterminate GlobeNewswire
Web2 Social Giant Wocute Enters Web3: FAWA's Innovative Path for Muslim Women
October 9, 2025

Web2 Social Giant Wocute Enters Web3: FAWA's Innovative Path for Muslim Women

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions